Race Oncology Ltd (ASX:RAC)
Last updated
Previous Close
Day Range
Year Range
Market Cap
Volume
P/E
Historical Yield (%)
Short Sell (%)
GICS Industry Group
GICS Sub-Industry Group
EPS
ROE (%)
ROA (%)
EBITDA Margin (%)
EBIT Margin (%)
NPAT Margin (%)
Inventory Turnover
Asset Turnover
Net Gearing (%)
Net Interest Cover
Current Ratio
About Race Oncology Ltd (RAC.AX)
Research & News
- Race Oncology (ASX:RAC) is a Potential Acquisition Target in a $530B M&A Market May 4, 2021 - Today we will take a look at why we like Race Oncology shares (ASX:RAC) and whether the RAC share price is worth buying at the moment. Race Oncology (ASX:RAC) is a precision oncology company with a phase II/III cancer drug called Bisantrene. The aim of the company is to build value in Bisantrene through proof-of-concept… Continue Reading
Are you looking for the best stocks to buy in 2021? We’ve put together a free report on 5 stocks that we think are the best buys on the ASX right now. Download it instantly here.
Information is provided ‘as is’ and solely for information purposes, not for trading purposes or advice.
Subscribe
Want more Free Research?
Subscribe today for free and get an alert when we have new research and webinars.
MF & Co. Asset Management
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Contact
Get In Touch
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000